



September 6, 2017

## **PDL BioPharma to Present at Two Upcoming Investor Conferences**

INCLINE VILLAGE, Nev., Sept. 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in September.

### **Rodman & Renshaw 19<sup>th</sup> Annual Global Investment Conference**

Monday, September 11, 2017, 10:25 a.m. EDT  
New York City

### **2017 Cantor Fitzgerald Global Healthcare Conference**

Monday, September 25, 2017, 9:10 a.m. EDT  
New York City

To access the live and subsequently archived webcasts of the presentations, go to the company's website at <http://www.pdl.com> and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentations to allow for any software download that may be necessary. The archived webcasts will be available for at least seven days following each presentation.

### **About PDL BioPharma**

PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 such transactions, of which 10 are active and outstanding. PDL has two debt transactions outstanding, representing deployed and committed capital of \$170.0 million: CareView and kaléo; one hybrid royalty/debt transaction outstanding, representing deployed and committed capital of \$44.0 million: Wellstat Diagnostics; and five royalty transactions outstanding, representing deployed and committed capital of \$396.1 million and \$397.1 million, respectively: KYBELLA®, AcelRx, University of Michigan, Viscogliosi Brothers and Depomed. PDL's equity and loan investments in Noden represent deployed and committed capital of \$179.0 million and \$202.0 million, respectively, and its converted equity and loan investment in LENSAR represents deployed capital of \$40 million.

NOTE: PDL, PDL BioPharma, the PDL logo and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary, to PDL BioPharma, Inc. which reserves all rights therein.



View original content with multimedia: <http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-two-upcoming-investor-conferences-300514383.html>

SOURCE PDL BioPharma, Inc.

